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Summary. Deep vein thrombosis (DVT) is associated with
coagulation abnormalities, but evidence of excess platelet
activity is scant. Soluble P-selectin is a marker of platelet
activity, with high levels being found in patients with
thrombotic disease. We measured soluble P-selectin by
enzyme-linked immunosorbent assay (ELISA) in plasma
from 89 patients with objectively conflrmed DVT and in 126
healthy age- and sex-matched control subjects, and found
higher levels in the patients (P = 0-011). Taking the risk of
DVT with a level of soluble P-selectin <238ng/ml to be l,
the relative risk of DVT with a soluble P-selectin level
>238ng/ml was 2-1 (95% CI 1-2-3-6). These high levels
may be a reflection of a generalized hypercoagulable state
that, with factors such äs the presence of persistent thrombin
generation, could be responsible for excess platelet activation.
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Deep vein thrombosis (DVT) is a common problem, with a
frequency of 1-3 per 1000 of the population each year
(Rosendaal, 1997). An important role of the clotting System
in the aetiology of thrombosis follows from the increased risk
associated with abnormalities in the System, both in the
anticoagulant (deficiencies in protein C, protein S and factor
V Leiden) and in the procoagulant (high levels of factor VIII
and factor II) Systems. The beneflcial prophylactic effect of
anticoagulants such äs heparin supports this concept.
Despite this, there is relatively little evidence suggestive of a
role for excessive platelet activity in DVT (van Hulsteijn et al,
1982). Nevertheless, an effect, albeit smaller than that for
heparin, has been shown for antiplatelet agents in the
prophylaxis of thrombosis, suggesting a role for platelet
activity in its aetiology (Research Committee of the British
Thoracic Society, 1992).
Adhesion molecules regulate leucocyte migration from
the circulation during inflammation and in other conditions.
One such molecule, P-selectin, is a membrane component of
the platelet alpha granule and endothelial cell Wiebel-
Palade body. A soluble form of P-selectin is present in the
plasma, and it has been suggested that increased levels are
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representative of platelet activation (Jilma et al, 1996; Blann
& Lip, 1997; Fijnheer et al, 1997). High levels have been
described in diseases such äs diabetes, atherosclerosis and
thrombotic consumptive platelet disorders, and fail to
correlate with platelet count (Chong et al, 1994; Ikeda et al,
1994; Jilma et al, 1996).
We therefore hypothesized that increased levels of soluble
P-selectin would be present in the blood of patients who have
had a DVT. As soluble P-selectin is influenced by smoking
(Blann et al, 1997), we included this factor in our analysis.
MATERIALS AND METHODS
We tested our hypothesis by measuring soluble P-selectin in
the plasma of a subgroup of the 474 participants in the
Leiden Thrombophilia Study, who were recruited from three
thrombosis Services in The Netherlands. Exclusion criteria
were malignancy, age less than 70years and recent
(< 3 months) use of coumarin derivatives. Each patient was
matched to a healthy community-based subject of the same
sex within 5 years of age. Venesection was performed a
median of 18 months (ränge 6-48 months) after their
objectively proven DVT. Füll details of this study are available
elsewhere (Koster et al, 1995; van der Meer et al, 1997).
Venous blood was obtained from an antecubital vein, and
citrated plasma was collected after centrifugation at 2000g
2000 Blackwell Science Ltd 191
192 Short Report
for 10min at room temperature and then stored at — 70°C.
Plasma was shipped to the UK in dry ice. All the plasma
samples had been thawed and refrozen for another project.
Thus, plasmas were thawed a second time and tested in large
batches for soluble P-selectin by commercial enzyme-linked
immunosorbent assay (ELISA; Takara-Shuzo, Japan). The
intra-assay coefficient of Variation of this assay was < 5%;
interassay variance was < 10%.
We hypothesized that soluble P-selectin would be
increased by about half a Standard deviation (i.e. from
200ng/ml in control subjects to 235 ng/ml in the patients,
being 17-5%). Thus, for a power of 90% (i.e. 1-beta) to defme
an alpha of 2p<0-05, we would need data from a minimum
of 200 subjects. Thus, from the 602 samples of available
plasma, 215 were selected for analyst-blind measurement of
soluble P-selectin. Results were returned to The Netherlands
for code breaking, which revealed that results had been
obtained from 89 cases and 126 controls. Data were
analysed for odds ratio, £-test or the chi-squared test, äs
appropriate, and is presented äs mean and 95% confldence
interval (CI) or percentage incidence.
RESULTS
Mean soluble P-selectin was 288 (95% CI 257-319) ng/ml
in the 89 patients (39% men, mean age 46 years) with a DVT
and was 242 (227-258) ng/ml in the 126 controls (41%
men, mean age 46 years), an increase in sP-selectin of 19%
(P = 0-011) (Fig 1). The difference in soluble P-selectin
between the groups was 46 ng/ml (95% CI of difference 30-
72 ng/ml). Overall, 35 patients and 73 controls had a level of
sP-selectin lower than the median level of the entire group
(238 ng/ml), whereas 54 (=61%) patients and 53 (=42%)
controls had levels above this flgure [a difference of 19%
(95% CI 6-32%), chi-square 6-81, P = 0-009]. Taking the
risk of DVT with a level of soluble P-selectin < 23 8 ng/ml äs
the reference, the excess relative risk (odds ratio) associated
with a soluble P-selectin level > 238 ng/ml was 2-1 (95% CI
1-2-3-6).
The group of 215 subjects included 63 current smokers,
22 (=25%) patients and 41 (= 32-5%) controls (P = 0-215,
chi-squared test). Mean soluble P-selectin was 276 (95% CI
249-303) ng/ml in the 63 smokers and 255 (233-277) ng/
ml in the 152 non-smokers (P = 0-028).
In a multiple regression analysis with soluble P-selectin äs
the dependent variable, the effect of group (i.e. patient or
control) retained significance (P = 0-004), but smoking lost
signiflcance (P = 0-157). A multivariate model (logistic
regression) with age, sex and smoking äs covariates led to
similar risk estimates.
DISCUSSION
Our study found increased levels of soluble P-selectin
following DVT and conflrms our previous observation of
the influence of smoking on soluble P-selectin (Blann et αϊ,
1997), although this effect is weak. The reasons for higher
levels than we expected (about 200-220 ng/ml) are unclear


















































Fig 1. Levels of soluble P-selectin in the plasma of cases and controls.
Open circles, smokers: closed circles, non-smokers.
between venepuncture and centrifugation, or centrifugation
for only 10 min at room temperature. However, whatever the
reason, it would have been constant between cases and
controls.
Membrane-bound P-selectin is found at the surface of
activated platelets and activated endothelial cells. Lack of
correlation with endothelial marker von Willebrand factor is
an example of a growing body of evidence that Supports the
hypothesis that increased levels of soluble P-selectin result
from platelet activation (Jilma et αϊ, 1996; Blann et αϊ, 1997;
FijnheereUi, 1997; Kawabata etal, 1998). Raised soluble P-
selectin in subjects who have suffered a DVT may indicate
excessive platelet activation, supporting other data reporting
raised beta thromboglobulin measured a few hours to 3 days
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after a proven DVT (van Hulsteijn et al. 1982) Unlike beta-
thromboglobulm, raised levels of soluble P-selectm are not
caused by ex vivo platelet activation, nor do they correlate
with platelet count (Chong et al, 1994, Jüma et al, 1996).
However, äs we took blood at least 6 months after the DVT
and 3 months after the discontmuation of oral anticoagula-
tion, we cannot discount the possibihty that raised soluble P-
selectm results from another difference between the patients
and the controls For example, soluble P-selectm may be
Imked to another coagulation factor, or may be associated
with post-thrombotic phenomena. Indeed, raised soluble P-
selectm may be the result of platelet activation by thrombin,
its fractions or other factors leadmg to a hypercoagulable
state, äs mdicated by changes in markers such äs fibnno-
peptide A, prothrombm l + 2 or thrombin-antithrombin Π
complex
Although we found raised soluble P-selectin m the group
of subjects who suffered a DVT, the wide scatter of data and
poor discrimmation imphed that this marker has little value
at the mdividual level. Nevertheless, it provides an mdication
that excess platelet activation may be related to the
development, or a consequence, of DVT.
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